A Strategic Partnership For Growth

Executive Summary

Therismos partnered with Amryt Pharmaceuticals from its inception to its acquisition by Chiesi Pharmaceuticals, providing a full-service operational platform enabling Amryt to establish its presence and scale rapidly in the rare disease market. By outsourcing supply chain, regulatory compliance and sales operations to Therismos, Amryt was able to focus on core activities while generating immediate revenue from its product portfolio. This long-term collaboration exemplifies Therismos’ ability to support healthcare companies at every stage of their lifecycle.

Introduction

Amryt Pharmaceuticals was founded in 2016 with a bold vision to become a global leader in the treatment of rare and orphan diseases. From its early days, Amryt recognised the need for a trusted partner to manage its operational processes, allowing it to focus on acquiring and developing a pipeline of promising drug candidates. Enter Therismos: a strategic partner offering turnkey operational services to support Amryt’s growth.

Challenges/Problems

As a young, rapidly expanding company, Amryt faced several challenges:

• Operational Setup: lack of an internal infrastructure for supply chain and distribution.
• Regulatory Compliance: need to comply with strict pharmaceutical regulations, including Good Distribution Practice (GDP).
• Time-to-Market Pressure: early acquisition of marketable products demanded immediate sales capabilities.

Solution

Therismos provided Amryt with a comprehensive operational service, from order-to-cash management to packaging, compliance with the falsified medicines directive and export sales. The ready-made solution eliminated the need for Amryt to build and staff an internal operations team or obtain and manage WDA(H) licenses, significantly reducing costs and enabling faster market entry.

Implementation

At the outset, Therismos took over full operational responsibility for Amryt’s first product acquisitions, managing procurement, storage, distribution and sales. As Amryt’s portfolio grew, Therismos scaled its services to match demand, maintaining a seamless supply chain while Amryt concentrated on its core business strategy.

Results/Outcomes

• Immediate Revenue: Therismos enabled Amryt to generate sales immediately after product acquisitions.
• Operational Efficiency: Therismos’ established processes ensured compliance and efficient market access across the UK and Europe.
• Strategic Growth: the partnership allowed Amryt to focus on its strategy of developing and acquiring orphan drug candidates, ultimately leading to its successful acquisition by Chiesi.

Key Takeaways

Therismos played a crucial role in Amryt’s journey from startup to acquisition, providing operational expertise and infrastructure that allowed the company to thrive. By outsourcing operations, Amryt was able to scale quickly without incurring the costs or delays associated with building and licensing in-house capabilities.